Anastrozole Improves Height Outcomes in Growing Children With Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency
Authors' conclusion
Anastrozole decreased the rate of bone maturation and led to improved height outcomes, indicating that anastrozole could have a role as an adjunct therapy in children with CAH and advanced bone age.
Study context
- Population
- Children with CAH due to 21-hydroxylase deficiency, advanced bone age (26 females; 52 classic, 8 nonclassic)26 females
- Participants
- 60 children
- Exposure
- Anastrozole treatment: change from baseline
- Anastrozolen = 60
- Outcome
- Z-scores of bone age, predicted adult height and height corrected for bone age
- Follow-up
- 8-year period
Methodological detailsrecords review, weighted mixed-effects models
- Records review
- Weighted mixed-effects models
Main finding
As reported in the abstract
Z-scores during anastrozole therapy · 4 and 6 years
- Mean bone age Z-score decreased from 4.2 to 2.0 at 4 years and 1.3 at 6 years (both P < .001)
- Predicted adult height Z-score improved from −2.1 to −0.45 at 4 years and 0.18 at 6 years (both P < .001)
- Corrected height Z-score improved from −1.7 to −0.33 at 4 years and 0.18 at 6 years (P < .001)
- Adjusted for sex, diagnosis, age at diagnosis, average hydrocortisone dose
Observational data: associations, not effects.
Further findings
Average total daily hydrocortisone dose before vs during treatment
- No significant difference
Original publication
Anastrozole Improves Height Outcomes in Growing Children With Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency. J Clin Endocrinol Metab. Published 4 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →